Mesoblast (MESO) EBITDA Margin (2014 - 2023)
Mesoblast's EBITDA Margin came in at 222.06% for the year ended Jun 30, 2026, down 316.29 percentage points from 538.34% a year earlier.
Analysis
Mesoblast (MESO) EBITDA Margin (2014 - 2023) Analysis & Trends
Going back to the year ended Jun 30, 2015, Mesoblast's EBITDA Margin data covers 12 years.
- EBITDA Margin carries a five-year change of +1649.01 percentage points (years ended Jun 2021 to Jun 2026).
- The figure for the year ended Jun 30, 2026 represents the lowest annual EBITDA Margin since the year ended Jun 30, 2022.
- Per Business Quant, earlier years put EBITDA Margin at 538.34% in the year ended Jun 30, 2025 (-736.89 pp), 1275.23% in the year ended Jun 30, 2024 (+50.01 pp), 1225.22% in the year ended Jun 30, 2023 (+2248.57 pp) and -1023.35% in the year ended Jun 30, 2022 (+403.61 pp).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 39.16% |
| 10 | Mesoblast | 1.66 Bn | 1.23 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -775.13% |
| Mar 31, 2023 | -653.53% |
| Dec 31, 2022 | -809.93% |
| Sep 30, 2022 | -750.70% |
| Jun 30, 2022 | -723.88% |
| Mar 31, 2022 | -811.64% |
| Dec 31, 2021 | -820.10% |
| Sep 30, 2021 | -486.20% |
| Jun 30, 2021 | -1,122.81% |
| Mar 31, 2021 | -1,102.15% |
| Dec 31, 2020 | -918.21% |
| Sep 30, 2020 | -1,558.85% |
| Jun 30, 2020 | -4,430.39% |
| Mar 31, 2020 | -102.77% |
| Dec 31, 2019 | -1,014.73% |
| Sep 30, 2019 | -17.54% |
| Jun 30, 2019 | -996.19% |
| Mar 31, 2019 | -1,881.51% |
| Dec 31, 2018 | -1,306.90% |
| Sep 30, 2018 | -146.10% |
API Access
Mesoblast EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=MESO&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "MESO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=MESO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();